Skip to main content

Atara Biotherapeutics, Inc. (ATRA)

NASDAQ: ATRA · IEX Real-Time Price · USD
16.03 0.22 (1.39%)
Oct 22, 2021 4:00 PM EDT - Market closed
Market Cap1.34B
Revenue (ttm)7.42M
Net Income (ttm)-317.78M
Shares Out92.15M
EPS (ttm)-3.63
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume593,692
Open15.67
Previous Close15.81
Day's Range15.55 - 16.06
52-Week Range11.81 - 28.20
Beta2.26
AnalystsBuy
Price Target33.00 (+105.9%)
Est. Earnings DateNov 9, 2021

About ATRA

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies a...

IndustryBiotechnology
IPO DateOct 16, 2014
CEOPascal Touchon
Employees558
Stock ExchangeNASDAQ
Ticker SymbolATRA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for ATRA stock is "Buy." The 12-month stock price forecast is 33.00, which is an increase of 105.86% from the latest price.

Price Target
$33.00
(105.86% upside)
Analyst Consensus: Buy

News

Atara Biotherapeutics Presents New Magnetization Transfer Ratio Imaging Data and Two-Year Clinical Data from the Open...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to de...

1 week ago - Business Wire

Atara Biotherapeutics and Pierre Fabre Enter Strategic Collaboration to Commercialize Tabelecleucel (Tab-cel®)

SOUTH SAN FRANCISCO, Calif. & CASTRES, France--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA) and Pierre Fabre today announced an exclusive commercialization agreement for tabelecleucel (ta...

2 weeks ago - Business Wire

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative...

2 weeks ago - Business Wire

Atara Biotherapeutics to Present Phase 1 Study Update of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2021

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), today announced the upcoming full release of new translational data and two-year open-label extension (OLE) clin...

3 weeks ago - Business Wire

European Medicines Agency Grants Atara Biotherapeutics Accelerated Assessment of tab-cel® for the Treatment of Epstei...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative...

3 weeks ago - Business Wire

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative...

1 month ago - Business Wire

Atara Biotherapeutics to Participate in a Panel Discussion at the Citi 16th Annual BioPharma Virtual Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative...

1 month ago - Business Wire

Atara Biotherapeutics (ATRA) Reports Q2 Loss, Misses Revenue Estimates

Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of -3.41% and -38.77%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Atara Biotherapeutics Announces Second Quarter 2021 Financial Results and Operational Progress

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative...

2 months ago - Business Wire

Atara Biotherapeutics Appoints Cell Therapy and Oncology Commercialization Veteran Ameet Mallik to the Board of Direc...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative ...

2 months ago - Business Wire

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative ...

2 months ago - Business Wire

Atara Biotherapeutics to Announce Second Quarter 2021 Financial Results on Monday, August 9, 2021

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative...

2 months ago - Business Wire

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative...

3 months ago - Business Wire

Atara Biotherapeutics Joins the Rare Disease Company Coalition Alongside Industry Gamechangers

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative...

3 months ago - Business Wire

Why there is opportunity in biotech and the names to watch

Kevin Mahn, Hennion and Walsh chief investment officer, joins 'The Exchange' to discuss the names he's favoring in the pharma sector. For access to live and exclusive video from CNBC subscribe to CNBC P...

Other symbols:BLUEIBBSRPT
3 months ago - CNBC Television

Atara Biotherapeutics Reveals Long-Term Overall Survival Data in Solid Organ-Transplant Patients

Atara Biotherapeutics Inc (NASDAQ: ATRA) has announced a combined long-term overall survival (OS) analysis from three studies of tabelecleucel (tab-cel) in patients with Epstein-Barr virus-driven post-t...

4 months ago - Benzinga

Atara Biotherapeutics Presents Positive Tab-cel® Long-Term Overall Survival Data for Epstein-Barr Virus-Driven Post-T...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative...

4 months ago - Business Wire

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative...

5 months ago - Business Wire

Atara Biotherapeutics to Participate at the Cowen Virtual Oncology Innovation Summit

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T- cell platform to develop transformativ...

5 months ago - Business Wire

Atara Biotherapeutics Names Cell Therapy & Oncology Leader Cokey Nguyen, Ph.D. as Chief Scientific Officer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative...

5 months ago - Business Wire

Atara Biotherapeutics (ATRA) Reports Q1 Loss, Lags Revenue Estimates

Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 7.53% and -50.60%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Atara Biotherapeutics Announces First Quarter 2021 Financial Results and Operational Progress

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative...

5 months ago - Business Wire

Atara Biotherapeutics to Announce First Quarter 2021 Financial Results on Tuesday, May 4, 2021

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative...

5 months ago - Business Wire

7 Stocks That Could Double by Summer

These seven stocks may be risky, but they also have the potential for big returns -- as all of them are stocks that could double by summer. The post 7 Stocks That Could Double by Summer appeared first o...

6 months ago - InvestorPlace

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative...

6 months ago - Business Wire